

CITATION REPORT

List of articles citing

Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma

DOI: 10.1007/s00270-009-9750-0

CardioVascular and Interventional Radiology, 2010, 33, 541-5

Source: <https://exaly.com/paper-pdf/47812417/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
297	Imaging to optimize liver tumor ablation. 2010 , 2, 433-443		8
296	Intra-arterial therapies for hepatocellular carcinoma: where do we stand?. <i>Annals of Surgical Oncology</i> , 2010 , 17, 1234-46	3.1	70
295	Unenhanced and contrast-enhanced ultrasonography during hepatic transarterial embolization and chemoembolization with drug-eluting beads. <i>CardioVascular and Interventional Radiology</i> , 2010 , 33, 1215-22	2.7	14
294	Traitements du carcinome hpatocellulaire non accessible ^ un traitement curatif: actualit�. 2010 , 12, 615-622		
293	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. 2010 , 28, 3994-4005		306
292	Advances in image-guided intratumoral drug delivery techniques. 2010 , 1, 307-22		20
291	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52		121
290	Advances in regional chemotherapy of the liver. <i>Expert Opinion on Drug Delivery</i> , 2011 , 8, 1057-69	8	15
289	Locoregional therapy for hepatocellular carcinoma. <i>Clinics in Liver Disease</i> , 2011 , 15, 395-421, vii-x	4.6	14
288	Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2011 , 22, 1545-52	2.4	156
287	DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. <i>Expert Opinion on Drug Delivery</i> , 2011 , 8, 153-69	8	54
286	Experience Using Doxorubicin-Loaded DC Beads During Hepatic Chemoembolisation. 2011 , 35, 172-179		
285	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. 2011 , 54, 695-704		129
284	Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. 2011 , 55, 1332-8		121
283	First multimodal embolization particles visible on x-ray/computed tomography and magnetic resonance imaging. 2011 , 46, 178-86		37
282	Elasticity and viscoelasticity of embolization microspheres. 2011 , 4, 2161-7		33
281	Chemoembolization for hepatocellular carcinoma. 2011 , 46, 105-14		4

280	[Experience using doxorubicin-loaded DC Beads [®] during hepatic chemoembolisation]. 2011 , 35, 172-9		3
279	Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. <i>Annals of Surgical Oncology</i> , 2011 , 18, 431-8	3.1	34
278	Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography. 2011 , 36, 718-28		14
277	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. 2011 , 36, 677-83		18
276	Safety profile of sequential transcatheter chemoembolization with DC Bead [®] results of 237 hepatocellular carcinoma (HCC) patients. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 774-85	2.7	102
275	Transarterial therapies for hepatocellular carcinoma. 2011 , 12, 1057-73		29
274	Arterially directed therapies for hepatocellular carcinoma. 2011 , 197, W590-602		16
273	Transcatheter intraarterial therapies: rationale and overview. 2011 , 259, 641-57		174
272	Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. 2011 , 81 Suppl 1, 105-10		7
271	Drug delivery embolization systems: a physician's perspective. <i>Expert Opinion on Drug Delivery</i> , 2011 , 8, 1071-84	8	14
270	Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. 2012 , 42, 247-55		37
269	Local-regional treatment of hepatocellular carcinoma. 2012 , 262, 43-58		264
268	Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. 2012 , 198, 692-9		53
267	Hepatocellular carcinoma: natural history, current management, and emerging tools. 2012 , 6, 207-19		45
266	Chemoembolization in patients with hepatocellular carcinoma. 2012 , 1, 41-50		70
265	Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. 2012 , 199, 349-59		19
264	Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. 2012 , 23, 355-69		16
263	Current status of embolic agents for liver tumor embolization. 2012 , 17, 306-15		49

262	Hepatic arterial changes following iodized oil chemoembolization of hepatocellular carcinoma: Incidence and technical consequence. 2012 , 6, 21		3
261	Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. 2012 , 57, 1244-50		173
260	Chemoembolization for hepatocellular carcinoma. 2012 , 39, 503-9		85
259	Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 287-94	2.4	135
258	Hepatocellular Carcinoma. 2012 , 1005-1031		1
257	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. 2012 , 56, 1330-5		354
256	Clinical usefulness of the triaxial system in super-selective transcatheter arterial chemoembolization for hepatocellular carcinoma. 2012 , 53, 857-61		14
255	Midterm follow-up after DC-BEAD+TACE of hepatocellular carcinoma (HCC). 2012 , 81, 3857-61		10
254	Multimodal visibility of a modified polyzene-F-coated spherical embolic agent for liver embolization: feasibility study in a porcine model. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 1225-31.e2	2.4	13
253	Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 257-64.e4	2.4	87
252	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 1286-93.e1	2.4	22
251	Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 980-5	2.7	206
250	Quality-improvement guidelines for hepatic transarterial chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 765-74	2.7	54
249	Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?. <i>Japanese Journal of Radiology</i> , 2012 , 30, 560-6	2.9	46
248	Interventional therapies for hepatocellular carcinoma. 2012 , 12, 79-88		23
247	Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2012 , 30, 263-70	2.9	38
246	Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. 2012 , 22, 1101-9		50
245	Austrian Joint EHG-EIR-EHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. 2012 , 124, 104-10		12

244	Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. 2012 , 161, 338-50		87
243	Interventional radiological treatment of hepatocellular carcinoma: an update. 2012 , 74, 91-9		13
242	[Transarterial ablation of hepatocellular carcinoma. Status and developments]. 2012 , 52, 44-55		7
241	Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. 2013 , 34, 336-51		9
240	Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 1039-46	2.7	18
239	Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 449-59	2.7	69
238	Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. 2013 , 23, 805-15		9
237	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). 2013 , 33, 327-37		52
236	Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 257-65	2.4	8
235	Embolic Therapies. 2013 , 101-113		
234	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. 2013 , 108, 1252-9		99
233	Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. <i>Expert Opinion on Drug Delivery</i> , 2013 , 10, 679-90	8	22
232	Doxorubicin-loaded drug-eluting beads (DC Bead [®]) for use in transarterial chemoembolization: a stability assessment. <i>Journal of Oncology Pharmacy Practice</i> , 2013 , 19, 65-74	1.7	20
231	A new drug-loading technique with high efficiency and sustained-releasing ability via the Pickering emulsion interfacial assembly of temperature/pH-sensitive nanogels. 2013 , 73, 1537-1543		19
230	Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 301-6	2.4	65
229	Chemoembolization and radioembolization for hepatocellular carcinoma. 2013 , 11, 604-11; quiz e43-4		59
228	Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) - European Organisation for Research and Treatment of Cancer (EORTC) guidelines. <i>European Journal of Cancer</i> , 2013 , 49, 1509-10	7.5	21
227	Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. 2013 , 94, 53-9		9

226	Résultat et coût de la chimioembolisation hépatique avec des billes chargées chez 21 patients. 2013 , 94, 52-59			1
225	New progress of non-surgical treatments for hepatocellular carcinoma. 2013 , 30, 381			20
224	Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. 2013 , 84 Suppl 1, 28-33			10
223	Embolisation devices from biomedical polymers for intra-arterial occlusion and drug delivery in the treatment of cancer. 2013 , 207-239e			3
222	[Diagnosis of and therapy for hepatocellular carcinoma]. 2013 , 51, 1269-326			67
221	Chemoembolization of hepatocellular carcinoma. <i>Seminars in Interventional Radiology</i> , 2013 , 30, 3-11	1.6		131
220	Intermediate hepatocellular carcinoma: current treatments and future perspectives. <i>Annals of Oncology</i> , 2013 , 24 Suppl 2, ii24-9		10.3	59
219	Consider the perspectives: interventional radiology. 2013 , 47 Suppl, S43-6			
218	Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. 2013 , 33, 944-9			43
217	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2013 ,			
216	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3069-77		5.6	52
215	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. 2014 , 35, 8451-9			21
214	Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. 2014 , 20, 536-43			23
213	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 , 8, 71-6			105
212	Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2014 , 20, 333-41		3	4
211	Multimodal treatment of hepatocellular carcinoma. 2014 , 25, 430-7			65
210	Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 1012-7		2.4	16
209	Nonsurgical treatment for localized hepatocellular carcinoma. 2014 , 16, 373			11

208	Fabrication of a heparin-PVA complex hydrogel for application as a vascular access. 2014 , 102, 1426-33		9
207	Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. 2014 , 29, 920-5		79
206	Chemoembolization and radioembolization. 2014 , 28, 909-19		14
205	TACE performed in patients with a single nodule of hepatocellular carcinoma. 2014 , 14, 601		28
204	[Transarterial ablative therapy of hepatocellular carcinoma]. 2014 , 54, 685-93		0
203	Transarterial therapies for primary liver tumors. <i>Surgical Oncology Clinics of North America</i> , 2014 , 23, 323-51	2.7	8
202	Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. 2014 , 47, 184-90		20
201	Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 379-87, 387.e1-2	2.4	26
200	Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 1067-73	2.4	58
199	Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 248-55.e1	2.4	12
198	Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 1037-1044.e2	2.4	26
197	[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 3. Transarterial chemoembolization]. 2014 , 103, 87-92		2
196	Chemoembolization with DC Bead [®] for the treatment of hepatocellular carcinoma: an update. 2014 , 1, 205-214		3
195	Hepatocellular Carcinoma. 2015 , 2146-2165		
194	Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. 2015 , 2015, 435120		6
193	Development of Intra-Arterial Chemoembolization for Various Types of Cancer in Humans. 2015 , 61, 220-227		
192	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2015 ,		
191	Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. 2015 , 7, 2009-19		62

190	Minimal invasive treatments for liver malignancies. 2015 , 27, 659-667		6
189	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. 2015 , 3, 284-93		4
188	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504		10
187	Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. 2015 , 42, 981-9		19
186	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. 2015 , 277, 594-603		26
185	Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. <i>Journal of Vascular and Interventional Radiology</i> , 2015 , 26, 1112-21	2.4	7
184	Treatment of Liver Cancer. 2015 , 5, a021535		144
183	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504		15
182	New treatment modalities for hepatocellular cancer. 2015 , 17, 442		7
181	[Targeted radiological therapy of liver tumors]. 2015 , 55, 43-7		1
180	Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. 2015 , 25, 2779-88		14
179	An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. 2015 , 10, 9		4
178	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. <i>British Journal of Radiology</i> , 2015 , 88, 20140564	3.4	22
177	Transarterial chemoembolization: modalities, indication, and patient selection. 2015 , 62, 1187-95		163
176	Liver Tumors/Metastases (TAE/CTACE/DEB-TACE). 2015 , 238-246		
175	Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. 2015 , 205, 742-52		31
174	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. <i>Hepatology Research</i> , 2015 , 45, 190-200	5.1	60
173	Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. 2015 , 17, 52-65		17

172	PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. 2015 , 10, 507-17		3
171	Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2015 , 26, 1777-86	2.4	24
170	Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. 2015 , 57, 419-427		2
169	Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. 2015 , 57, 419-27		1
168	Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 1379-91	2.7	22
167	Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. 2016 , 50, 418-426		14
166	Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. 2016 , 200, 552-9		15
165	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. 2016 , 5, 1675		1
164	Interventieradiologie ̄opereren zonder snijden. 2016 , 32, 304-318		
163	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. 2016 , 48, 798-805		34
162	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. 2016 , 3, 109-118		2
161	Mechanisms of doxorubicin resistance in hepatocellular carcinoma. 2016 , 3, 57-59		77
160	Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors. 2016 , 280, 752-61		27
159	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. 2016 , 34, 2046-53		239
158	In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy. 2016 , 503, 150-62		17
157	DC BeadM1̄towards an optimal transcatheter hepatic tumour therapy. 2016 , 27, 13		26
156	Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. <i>Journal of Vascular and Interventional Radiology</i> , 2016 , 27, 39-45	2.4	13
155	Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. 2016 , 26, 1640-8		50

154	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. 2017 , 69, 67-73		14
153	Chemoembolization or Bland Embolization for Hepatocellular Carcinoma: The Question Is Still Unanswered. 2017 , 35, 256-257		6
152	Transarterial Therapies for Hepatocellular Carcinoma. 2016 , 6, 27-33		34
151	Liver blood flow. 2017 , 77-92.e5		
150	Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab. 2017 , 6, 1601291		30
149	Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. 2017 , 3, CD011649		13
148	Loco-regional treatment of HCC: current status. 2017 , 72, 626-635		50
147	Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. 2017 , 283, 702-710		30
146	Review article: delivering precision oncology in intermediate-stage liver cancer. 2017 , 45, 1514-1523		19
145	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e98	4.2	54
144	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 563-573	7.3	207
143	Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. 2017 , 209, 67-76		22
142	New concepts in embolotherapy of HCC. 2017 , 34, 58		42
141	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. 2017 , 14, 448-458		20
140	Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 502-512	2.4	20
139	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. 2017 , 18, 67		1
138	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 2017 , 24, 1073274817729244		18
137	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. 2017 , 149-178		

136	Traitements intra-artériels des carcinomes hépatocellulaires : évidence clinique et perspectives à venir. 2017 , 19, 158-167		
135	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 1210-1223.e3	2.4	69
134	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. 2017 , 5, 511-518		41
133	Hepatic artery embolization and chemoembolization of liver tumors. 2017 , 1398-1416.e4		
132	Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization. 2017 , 7, 2164-2176		13
131	Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2017 , 12, e0184597	3.7	59
130	Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. 2017 , 10, 4773-4785		6
129	Locoregional and systemic therapy for hepatocellular carcinoma. 2017 , 8, 215-228		46
128	Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. 2017 , 35, 258-259		1
127	Chemoembolization of liver cancer with drug-loading microsphere 50-100µm. <i>Oncotarget</i> , 2017 , 8, 5392-5399		9
126	Conventional drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. 2017 , 9, 808-814		56
125	Downstaging for hepatocellular cancer: harm or benefit?. 2017 , 2, 106		17
124	Are prophylactic antibiotics necessary prior to transarterial chemoembolization for hepatocellular carcinoma in patients with native biliary anatomy?. 2018 , 117, 1312-1317		10
123	Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy. <i>Journal of Vascular and Interventional Radiology</i> , 2018 , 29, 550-555	2.4	10
122	Liver Cancers. 2018 , 100-116		
121	Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. 2018 , 68, 1163-1171		6
120	Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. 2018 , 48, 555-564		18
119	Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. 2018 , 27, 69-80		10

118	Hepatocellular carcinoma treatment: ablation and arterial embolization. 2018 , 60, 156-166		1
117	Liver-directed therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2018 , 43, 203-217	3	8
116	TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis. 2018 , 53, 151-158		9
115	Chitosan-Based Hydrogel Microparticles for Treatment of Carcinoma in a Rabbit VX2 Liver Tumor Model. <i>Journal of Vascular and Interventional Radiology</i> , 2018 , 29, 575-583	2.4	1
114	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. 2018 , 9, 734-740		14
113	Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. <i>World Journal of Gastroenterology</i> , 2018 , 24, 161-169	5.6	63
112	Interventional Radiology in Oncology. 2018 , 41-61		
111	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv238-iv255	10.3	355
110	Minimal Risk of Biliary Tract Complications, Including Hepatic Abscess, After Transarterial Embolization for Hepatocellular Carcinoma Using Concentrated Antibiotics Mixed with Particles. <i>CardioVascular and Interventional Radiology</i> , 2018 , 41, 1391-1398	2.7	4
109	Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. 2018 , 7, 312-322		4
108	Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. 2018 , 9, 2640-2649		6
107	Primary Malignant Neoplasms of the Liver. 2018 , 705-729		1
106	Nanomedicinal delivery systems for intelligent treatment of hepatocellular carcinoma. 2019 , 53, 101152		1
105	Survival, tumour response and safety of 70-150 �h versus 100-300 �h doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma. 2019 , 63, 802-811		11
104	Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. 2019 , 293, 695-703		6
103	Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. 2019 , 8, 4200-4213		5
102	Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study. 2019 , 27, 583-592		5
101	Is Idarubicin the Future of TACE?. 2019 , 291, 809-810		1

100	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. 2019 , 8, 326-340		19
99	Controversies in the management of hepatocellular carcinoma. 2019 , 1, 17-29		26
98	Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. 2019 , 49, 170-181		3
97	Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2019 , 28, 717-729	2.7	4
96	Recent advances in medical management of hepatocellular carcinoma. <i>Hepatology Research</i> , 2019 , 49, 14-32	5.1	41
95	Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 507-510	1.7	1
94	Liver and Bile Duct Cancer. 2020 , 1314-1341.e11		3
93	Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2433-2441	4	2
92	Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?. <i>Clinics in Liver Disease</i> , 2020 , 24, 681-700	4.6	2
91	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. <i>Cancers</i> , 2020 , 12,	6.6	23
90	Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 7337	2.6	3
89	Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. <i>Seminars in Interventional Radiology</i> , 2020 , 37, 441-447	1.6	2
88	Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline. <i>Current Oncology</i> , 2020 , 27, e106-e114	2.8	5
87	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 99	12.8	16
86	Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. <i>Cancers</i> , 2020 , 12,	6.6	41
85	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020 , 31, 334-351	10.3	64
84	Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. <i>PLoS ONE</i> , 2020 , 15, e0227711	3.7	4
83	Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 347	5.3	9

82	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021 , 73 Suppl 1, 137-149	11.2	25
81	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. <i>Diagnostic and Interventional Radiology</i> , 2021 , 27, 85-93	3.2	1
80	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1499-1510	3.1	1
79	A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. <i>Drug Delivery</i> , 2021 , 28, 240-251	7	2
78	Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2021 , 39, 494-502	2.9	1
77	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021 , 13,	6.6	6
76	Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. <i>European Radiology Experimental</i> , 2021 , 5, 10	4.5	1
75	Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. <i>Drug Delivery and Translational Research</i> , 2021 , 1	6.2	2
74	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. <i>Abdominal Radiology</i> , 2021 , 46, 3540-3548	3	2
73	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 403-419	5.3	10
72	A Water-Based Liquid Embolic: Evaluation of its Safety and Efficacy in a Rabbit Kidney Model. <i>Journal of Vascular and Interventional Radiology</i> , 2021 , 32, 813-818	2.4	1
71	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 738-748	5.2	2
70	Interventional Treatment for Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 671327	5.3	2
69	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. <i>JCO Oncology Practice</i> , 2021 , OP2100227	2.3	1
68	Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. <i>Medicinal Research Reviews</i> , 2022 , 42, 374-398	14.4	3
67	Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8 T-Cell Infiltration in Rabbit VX2 Liver Tumor. <i>Cancer Management and Research</i> , 2021 , 13, 6943-6952	3.6	1
66	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 661-671	2.1	4
65	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. <i>European Journal of Cancer</i> , 2021 , 157, 373-382	7.5	1

64	Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2021 , 18, 383-398	8	5
63	Intra-arterial Chemotherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma. 2021 , 171-187		
62	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. <i>Korean Journal of Radiology</i> , 2021 , 22, 1658-1670	6.9	2
61	Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. <i>Drug Delivery and Translational Research</i> , 2021 , 11, 1924-1942	6.2	4
60	Transarterial therapies for hepatocellular carcinoma. <i>Recent Results in Cancer Research</i> , 2013 , 190, 195-206	10.5	13
59	The Liver. 2012 , 1411-1475		5
58	Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 437-43	2.2	92
57	Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e102686	3.7	21
56	A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. <i>Oncotarget</i> , 2017 , 8, 5460-5473	3.3	1
55	Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. <i>Oncotarget</i> , 2017 , 8, 15101-15113	3.3	14
54	The role of microRNA in the resistance to treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2019 , 7, 577	3.2	26
53	Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. <i>The Korean Journal of Hepatology</i> , 2011 , 17, 51-60		24
52	Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5622-5632	5.6	44
51	Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17206-17	5.6	28
50	Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 221-31	5.6	27
49	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015 , 27, 96-121	3.8	51
48	Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2015 , 21, 175-80	3	33
47	Locoregional treatment for hepatocellular carcinoma: The best is yet to come. <i>World Journal of Radiology</i> , 2015 , 7, 306-18	2.9	18

46	Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. <i>Journal of the Belgian Society of Radiology</i> , 2019 , 103, 47	0.6	8
45	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 541-565	7.3	74
44	Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 3595-604	1.7	65
43	Interventionelle Radiologie. 2010 , 341-352		
42	Principles of Liver Embolization. 2012 , 95-106		1
41	Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. 2013 , 327-338		
40	Transvaskuläre Therapie des hepatozellulären Karzinoms. 2013 , 299-322		1
39	Interventional Radiology in Oncology. 2014 , 43-63		
38	Liver and Bile Duct Cancer. 2014 , 1373-1396.e8		1
37	Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016 , 7, 764-778	0.7	1
36	Hepatocellular Carcinoma. 2018 , 668-692.e9		1
35	Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. 2020 , 311-322		
34	Transarterial Yttrium-90 Radioembolization of Hepatocellular Carcinoma Perfused by the Cystic Artery: Multi-institutional Feasibility Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 2022-2027	2.4	1
33	Chemoembolization for Hepatocellular Carcinoma. 2020 , 282-286.e2		
32	Physics and Physiology of Transarterial Chemoembolization and Drug-Eluting Beads for Liver Tumors. 2020 , 29-42		
31	Radiology, Interventional. 2020 , 343-366		
30	Transarterial Chemoembolisation and Combined Therapy. <i>Medical Radiology</i> , 2021 , 283-317	0.2	
29	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2020 , 24, 1-264	4.4	2

28 Onkologische Embolisation. **2021**, 409-504

27 A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2021**, 21, 101-107, 3.8 10

26 Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. *International Journal of Clinical and Experimental Medicine*, **2014**, 7, 3892-903 13

25 Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. *CardioVascular and Interventional Radiology*, **2021**, 45, 54 2.7

24 Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. *Expert Opinion on Investigational Drugs*, **2021**, 1-13 5.9 1

23 Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 1445-1458 5.3 0

22 Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2021**, 22, 1-12 6.3 0

21 The trends and efficacy of operation in the treatment of hepatocellular carcinoma.. *Translational Cancer Research*, **2022**, 11, 148-159 0.3

20 Use of chemotherapy to treat hepatocellular carcinoma.. *BioScience Trends*, **2022**, 16, 1-10 9.9 1

19 Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria.. *Clinics and Research in Hepatology and Gastroenterology*, **2022**, 101893 2.4 1

18 Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.. *Cancers*, **2021**, 13, 1-12 6.6 1

17 Data_Sheet_1.PDF. **2020**,

16 Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019.. *Cancers*, **2022**, 14, 1-12 6.6

15 Interventional Radiology of the Liver. **2015**, 1498-1519

14 Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. *Cancers*, **2022**, 14, 2469 6.6 1

13 Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients with Inoperable Hepatocellular Carcinoma. *Clinical and Translational Gastroenterology*, **2022**, Publish Ahead of Print, 4.2

12 Intraarterial Therapies for the Management of Hepatocellular Carcinoma. *Cancers*, **2022**, 14, 3351 6.6 1

11 Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. *British Journal of Radiology*, 3.4 2

10	Zytostatikabeschichtete Beads. 2022 , 1-8	0
9	Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. 2022 , 42, 1670-1689	1
8	Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma. 13,	0
7	Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma. 2022 , 22,	0
6	Nonsurgical Treatment for Localised Hepatocellular Carcinoma. 69-75	0
5	Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer. 14, 2367-2379	0
4	Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.	0
3	Photomodulated Extrusion as a Localized Endovascular Hydrogel Deposition Method. 2202632	0
2	Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. 2023 , 115, 102526	0
1	Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study. 14,	0